RWD161 Real World Utilization of Androgen Deprivation Therapy Among Urology Practices: Characterizing Initiation and Transition to Relugolix for Patients with Prostate Cancer (THE REAL ADT TRANSITIONS STUDY)

Abstract

Relugolix was FDA approved in December 2020 as the first oral gonadotropin releasing hormone (GnRH) receptor antagonist to treat advanced prostate cancer and became commercially available in January 2021. Previous studies have documented transitions between injectable GnRH agonists and antagonists. This study examined the real-world utilization of relugolix during its first year of availability (January – December 2021) and documented transitions between injectable and oral androgen deprivation therapy (ADT).